Oxford Biomedica plc (LON:OXB) Receives GBX 663.67 Average Target Price from Analysts

Shares of Oxford Biomedica plc (LON:OXB) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is GBX 663.67.

Several equities analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft raised their price target on shares of Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a research note on Friday, January 9th. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 950 target price on shares of Oxford Biomedica in a research note on Wednesday.

Oxford Biomedica Stock Performance

Shares of OXB stock opened at GBX 632 on Wednesday. Oxford Biomedica has a 52 week low of GBX 232.50 and a 52 week high of GBX 952. The company has a market capitalization of £763.91 million, a price-to-earnings ratio of -17.45 and a beta of 1.04. The company has a 50-day simple moving average of GBX 764.42 and a 200 day simple moving average of GBX 661.68. The company has a debt-to-equity ratio of 322.11, a quick ratio of 1.67 and a current ratio of 1.89.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.